Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELANFIT: Cetuximab, Carboplatin, and 5-FU in Elderly Fit Patients with HNSCC
NCT01864772Phase 2Completed
- Sponsor
- GORTEC
- Start
- Sep 2013
- Primary completion
- Apr 2020
- Modality
- Antibody Conjugates, Monoclonal Antibodies, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of cetuximab, carboplatin, fluorouracil in head and neck squamous cell carcinoma (HNSCC), sponsored by GORTEC. Started Sep 2013; status: completed.
02
Drugs
cetuximabcarboplatinfluorouracil
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT01864772.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01864772.